By Karen Roman
VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund.
The company also applied for a Nasdaq listing under the ticker symbol “VRXA” via a combination with Voyager Acquisition Corp. (Nasdaq: VACH) and to advance its cancer therapies pipeline, VERAXA stated.
“Securing these financings marks a significant step in our ongoing business combination with Voyager Acquisition Corp. and the expected listing of VERAXA shares on NASDAQ,” said Torsten Bürgermeister, VERAXA’s CFO. “We appreciate the financial support of these investors as we continue to employ a disciplined approach to balance sheet management through efficient and flexible access to capital.”d
READ MORE
Save the Date: 2nd LA CorpGov Forum Sep 18 Featuring Sports, Entertainment & M&A
Never Miss our Weekly Highlights HERE
